Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $290
Cantor Fitzgerald analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $285 to $290.
Stocks · News reference
AbbVie Receives Two New FDA's Breakthrough Therapy Designations For Telisotuzumab Adizutecan In Colorectal Cancer, Non-Small Cell Lung Cancer
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted two Breakthrough Therapy Designations (BTDs) for telisotuzumab adizutecan (Temab-A; ABBV-400) in colorectal cancer (CRC)
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why is AbbVie (ABBV) Stock Trending After Hours?
AbbVie Inc. Shares rose 0.44% after hours following FDA breakthrough designations for telisotuzumab adizutecan in two cancers.
9 Of 11 Sectors Fall Wednesday As Defensives Lead
Two of 11 sectors are higher in Wednesday's regular session, with defensive sectors holding the top three positions. The leaders are separated rather than clustered, with Health Care and Consumer Staples above the rest of the table.
Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $310
Morgan Stanley analyst Terence Flynn maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $296 to $310.